Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration for Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy for Metastatic Urothelial Cancer
On January 6, 2021, Everest Medicines (HKEX 1952.HK) announced that the National Medical Products Administration (NMPA) of the People’s Republic of China approved a Clinical Trial Application (CTA) for sacituzumab govitecan-hziy for the treatment of patients with metastatic urothelial cancer (mUC). With this CTA, Everest Medicines plans to enroll patients in China as part of the Phase 3, global, multicenter, open-label randomized controlled TROPiCS-04 trial. Patients will be randomized to receive either sacituzumab govitecan-hziy or Treatment of Physician’s…